CMA clarifies collaboration on combination therapies to accelerate patient access to essential treatments

The Competition and Markets Authority (CMA) today issued a statement clarifying that certain types of agreements between competing pharmaceutical companies working on ‘combination therapies’ will not be prioritized for research – making it easier for pharmaceutical companies to work together to deliver essential to develop treatments for use in NS. The CMA’s statement comes in…